

# Prevalence of Dyslipidemia and its association with disease activity in patients with Rheumatoid Arthritis In Sulaimani Governorate

## Abstract

**Background:** Rheumatoid Arthritis is a systemic inflammatory disease characterized by chronic and erosive polyarthritis .it is the most common inflammatory arthritis , affecting from 0.5-1% of the general population.

Dyslipidemia is a quite important problem in Rheumatoid Arthritis (RA) patient, which causes morbidity and mortality. As known, dyslipidemia is one of atherosclerosis risk-factor, and main mortality cause of longstanding RA patient.

**Objectives:** are to measure Prevalence of dyslipidemia in patients with Rheumatoid Arthritis compared with healthy control peoples and to find out correlations between Dyslipidemia and disease activity in patients with Rheumatoid Arthritis.

**Patients and Methods:** A total of one hundred patients with RA ( 80 female and 20 male )were included in the study, they were attending Consultation clinic and division of Rheumatology in the General Medical Teaching Hospital in Slemani city from (October 2015 to September 2016) who fulfilling the 2010 American College of Rheumatology/European league against Rheumatism classification criteria for RA and one hundred healthy age and sex-matched controls. Fasting lipid profiles of cases and control were estimated after an overnight fast of 12 hours. Association between lipid profile and disease activity using disease activity score DAS 28, inflammatory markers (CRP and ESR) was also determined.

**Results:** RA patients showed a higher prevalence of associated dyslipidemia (48%) in comparison to control (4%) p- value less than 0.001.

Our result showed a significant reduction in serum high density lipoproteins (HDL) p-value less than 0.001, with significant elevation of serum total cholesterol, triglyceride, low density lipoprotein and very low density lipoprotein p-value 0.001,0.007,0.01and 0.5 respectively in comparison to controls.

there is a significant association between dyslipidemia and high DAS 28 score (p=0.02).

there is a significant association between high ESR of RA patients and dyslipidemia (p=0.001). A significant association was observed between high CRP level and RA patients with no dyslipidemia (p<0.001).

**Conclusion:** Dyslipidemia are frequent among the patients with rheumatoid arthritis and highly associated with active RA. Serum HDL significantly reduced while other parameters of lipid profiles significantly increased in comparisons to control.

**Keywords:** Rheumatoid arthritis, Dyslipidemia, Disease activity.

## **Introduction :**

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by chronic and erosive polyarthritis<sup>(1)</sup>, associated with persistent inflammatory synovitis, progressive joint destruction, and an excess mortality when compared to the general population.<sup>(2,3)</sup>

It is characterized by symmetric erosive synovitis<sup>(3)</sup>. Female are 2.5 times more likely to be affected than male<sup>(4)</sup>.

The onset of disease can occur at any age but peak incidence occurs within fourth and fifth decade of life<sup>(5)</sup>

Its clinical diagnosis made on the basis of symptoms, physical examinations, X-ray and laboratory investigations<sup>(6)</sup>.

Patients with RA have an increased mortality when compared with age-matched controls, primarily due to cardiovascular disease. This is most marked in those with severe disease, with reduction in expected life span by 8-15 years<sup>(7)</sup>.

Dyslipidemia are being increasingly recognized as an important contributory factor toward the development of cardiovascular disease<sup>(8)</sup>.

Premature cardiovascular disease (CVD) is very common in RA patients<sup>(9, 10)</sup>. RA is associated with 50% increase in incidence of myocardial infarction (MI) and cardiovascular diseases as compared to general population<sup>(10)</sup>.

It has been observed that increased inflammation and active disease has an impact on lipid patterns in blood<sup>(11)</sup>.

Atherosclerosis is now considered as an inflammatory disease as it is a result of inflammation and inflammatory cytokines are prevalent in atherosclerotic plaques<sup>(12,13)</sup>.

Although dyslipidemia in RA may be partially governed by a genetic predisposition, it is also influenced by an array of other factors including disease activity<sup>(14)</sup>, reduced physical activity secondary to pain, disability<sup>(14)</sup>, and drug therapy<sup>(15-17)</sup>.

Dyslipidemia is highly prevalent in RA affecting between 55-65% of patients<sup>(18,19)</sup> and can manifest in RA patients with both early<sup>(20)</sup> and advanced disease<sup>(21)</sup>. The Disease Activity Score 28 (DAS28) is a major scoring system for evaluating disease activity of RA. In clinical practice CRP and ESR are used in monitoring

disease activity and response to the treatment. CRP.<sup>(22)</sup>

## **Patients and methods**

**Study design and setting:** A prospective case control was done

This study was conducted at Rheumatology Unit, outpatient clinic in Sulaimani Teaching Hospital, Sulaimani city. The study was carried out over 12 months from October 2015 to September 2016.

## **Sampling**

This study included one hundred patients with RA (80 female and 20 male) fulfilling the 2010 American College of Rheumatology/European league against Rheumatism classification criteria for RA and one hundred healthy sex and age-matched controls.

patients and controls' age were between 20-70 years old.

## **Exclusion criteria:**

History of smoking or patients suffering from condition that affect the lipid profile such as Diabetes mellitus, Hypertension, Ischemic heart disease, renal impairment, liver and thyroid functional abnormalities, Cushing syndrome and obesity (BMI >30) were excluded.

Also any patients received medications affecting lipid metabolism such as beta blocker, diuretics, cyclosporine, oral contraceptive pills (OCP), patients who received oral or intra-articular steroid till one month before study and pregnant women were excluded.

## **The study protocol:**

The study protocol includes:- (Questionnaire, clinical examination of RA patients, Disease Activity Score (DAS 28), Laboratory investigations)

-Laboratory investigations include : (ESR),(RFT), (LFT), (TSH), (FBS or RBS), (ECG), lipid profile .immunological tests, (CRP), (ACCP) .

The **body mass index (BMI)** was also measured for all patients

## **Questionnaire:**


A protocol was designed to obtain data about the name, age, occupation, residence of the patients, weight, height, and drug history, duration of the disease, history of chronic disease, and history of smoking, number of tender and swollen joints. The results of investigations (RF, ESR, CRP, lipid profile, RFT, LFT, TFT, and ACCP) were recorded on the same questionnaire ..

**Statistical analyses:**

All patients' data entered using computerized statistical software; Statistical Package for Social Sciences (SPSS) version 17 was used. Descriptive statistics presented as (mean ± standard deviation) and frequencies as percentages. Kolmogorov Smirnov analysis verified the normality of the data set. Multiple contingency tables conducted and appropriate statistical tests performed, Chi-square used for categorical variables and Fishers exact test was used when more than 20% of the cells less than 5. In all statistical analysis, level of significance (p value) set at ≤ 0.05 and the result presented as tables and/or graphs. Statistical analysis of the study was done by the community medicine specialist.

**Results**


A total 100 rheumatoid arthritis (RA) patients were included in present study with mean age of as 57±8.6 years, 36% of them were 50-59 years age. Females were more than males with female to male ratio as 4:1.




Gender distribution of RA patients.

Disease duration distribution of RA patients


RA disease duration of studied patients, 52% of them had disease duration of more than 5 years



Mean DAS 28 score of RA patients was 5.3±1.9, 46% of RA patients had moderate score and 35% of RA patients had high score\





Age distribution of RA patients.



DAS 28 scores distribution of RA patients.

Mean cholesterol level of RA patients was  $174.5 \pm 42.8$  mg/dl, 27% of them had high cholesterol level. Mean triglycerides level of RA patients was  $132.1 \pm 56.4$  mg/dl, 37% of RA patients had high Tg level. Mean LDL level of RA patients was  $101.9 \pm 39.5$  mg/dl, 18% of RA patients had high LDL level. Mean VLDL level of RA patients was  $29.8 \pm 14.8$  mg/dl, 38% of RA patients had high VLDL level. Mean HDL level of RA patients was  $55 \pm 18.6$  mg/dl, 38% of RA patients had low HDL level. Dyslipidemia was detected among 48% of RA patients.

Lipid profile of RA patients.




Dyslipidemia distribution of RA patients.

There was a significant association between high cholesterol level and RA cases ( $p=0.001$ ). High triglycerides level was significantly higher among RA patients ( $p=0.007$ ). A significant association was observed between high

LDL level and RA cases ( $p=0.01$ ). A significant differences were observed between RA cases and controls regarding VLDL level ( $p=0.5$ ). Low HDL level was significantly higher among RA cases ( $p<0.001$ ). Generally, Dyslipidemia was significantly higher among RA patients ( $p<0.001$ ).

Distribution of lipid profile according to RA cases and controls.

Variable	RA cases		Control		$\chi^2$	P
	No.	%	No.	%		
<b>Cholesterol level</b>					9.5	<b>0.001</b>
Normal	73	73.0	90	90.0		
High	27	27.0	10	10.0		
<b>Tg level</b>					7.1	<b>0.007</b>
Normal	63	63.0	80	80.0		
High	37	37.0	20	20.0		
<b>LDL level</b>					5.3	<b>0.01</b>
Normal	82	82.0	93	93.0		
High	18	18.0	7	7.0		
<b>VLDL level</b>					0.2	<b>0.05</b>
Normal	67	62.0	73	70.0		
High	33	38.0	27	30.0		
<b>HDL level</b>					14.9	<b>&lt;0.001</b>
Normal	62	62.0	86	86.0		
Low	38	38.0	14	14.0		
<b>Dyslipidemia</b>					50.3	<b>&lt;0.001</b>
Yes	48	62.0	4	4.0		
No	52	38.0	96	96.0		




Dyslipidemia in RA cases and controls.

No significant differences were observed between male and female RA cases regarding lipid profile

Distribution of RA patients' lipid profile according to gender.

Variable	Male		Female		$\chi^2$	P
	No.	%	No.	%		
Dyslipidemia					0.04	0.8
Yes	10	50.0	38	47.5		
No	10	50.0	42	52.5		

There was a significant association between dyslipidemia and high DAS 28 score (p=0.02).



Dyslipidemia distribution in RA disease activity.

There was a significant association between high ESR of RA patients and dyslipidemia (p=0.001). A significant association was observed between high CRP level and RA patients with no dyslipidemia (p<0.001).

Variable	Dyslipidemia		No dyslipidemia		$\chi^2$	P
	No.	%	No.	%		
ESR					10.4	0.001
Normal	5	10.4	20	38.5		
High	43	89.6	32	61.5		
CRP					39.9*	<0.001
Positive	15	47.9	48	77.0		
Negative	33	52.1	4	23.0		

\*Fisher's exact test.

Distribution of RA patients' ESR and CRP according to dyslipidemia of RA patients.

## discussion

Several pieces of evidence indicate that rheumatoid arthritis (RA) is a proatherogenic disease associated with increased cardiovascular (CV) mortality<sup>(23)</sup> which account for about half of all

deaths in these patients<sup>(24)</sup>. Besides genetic and traditional CV risk factors,<sup>(25)</sup> chronic inflammation has effect in the development of this process.<sup>(26)</sup>

Results showed that RA occurs in all age groups between 20-70 years, which showed that 36% of them between 50 to 59 years & 26% were between 40 to 49 years of age; this is in accordance with other study which mentioned that RA affects usually people above 40 years old<sup>(27)</sup>.and also matched with the study done by Abdul Qahar ZH et al in Baghdad, Iraq 2013<sup>(28)</sup>.

The prevalence of dyslipidemia among RA patients in present study was 48%. This prevalence is close to results of Haya Salinas MJ et al in Argentin<sup>(29)</sup> that reported dyslipidemia prevalence in RA patients as 43%, on other hand, Akiyama et al study in Japan<sup>(30)</sup> showed that 56.5% of RA patients had dyslipidemia.<sup>(31)</sup>

Patients with rheumatoid arthritis (RA) have higher rates of morbidity and mortality than the general population, which is highly attributed to an increased risk of cardiovascular disease (CVD) among RA patients<sup>(32)</sup>. The increased risk of CVD appears to be linked to coronary atherosclerosis<sup>(33)</sup> and may be directly caused by chronic inflammation or secondarily caused by physical inactivity and drugs used to treat RA<sup>(34)</sup>.

In this study we found that patients diagnosed with RA had significantly reduced levels of HDL-cholesterol in comparison to control groups and this was matched with many other study done in all of Pakistan 2012 by Nisar A et al<sup>(35)</sup>, Tunisia 2011 by Zrour SH et al<sup>(36)</sup>, Malaysia 2012 by Manjunatha Goud BK et al<sup>(37)</sup>, South India by Vinapamula KS et al<sup>(38)</sup>, Saudi Arabia 2013 by Bahlas S et al<sup>(39)</sup>, Bagdad, Iraq 2013 by Ameer KH et al by Georgiadis AN et al<sup>(40)</sup> and United Kingdom 2011<sup>(41)</sup> which is unfavorable profile with regard to cardiovascular risks<sup>(42)</sup> and there was no study against it.

Our study revealed a significantly higher cholesterol level of RA patients in comparison to controls (p=0.001). This is

consistent with Attar study in Saudi Arabia<sup>(43)</sup>

In present study, blood levels of triglycerides and LDL cholesterols of RA patients were significantly higher than healthy controls with significantly lower HDL cholesterol level. These findings are similar to results of previous Spanish study done by Gonzalez Gay MA et al<sup>(44)</sup>.

Regarding HDL-cholesterol, it has been reported that patients with active RA consistently demonstrate reduced levels<sup>(45)</sup>.

Also in our study Serum VLDL level of RA patients was significantly higher than healthy controls. This finding coincides with Al-Kaissi et al study in Jordan<sup>(46)</sup> reported high VLDL prevalence among RA patients. but Inconsistently with our results, Al-Chetachi and Shaher study<sup>(47)</sup> in Iraq reported no significant difference in VLDL and Tg levels between RA and healthy controls.

In general, dyslipidemia was significantly noted in RA patients in present study ( $p < 0.001$ ). This is consistent with results of Mahdi et al study in Iraq<sup>(48)</sup> and Curtis et al study in USA<sup>(49)</sup>.

In our study, the RA activity (DAS) was significantly high among RA patients with dyslipidemia ( $p = 0.02$ ). This is consistent with results of Georgiadis et al study in Greece<sup>(50)</sup>.

Our Results showed that ESR and CRP levels were significantly higher among RA patients with dyslipidemia. These findings are significant to results of Curtis et al study in USA<sup>(49)</sup>. Inflammation is a common denominator in both RA and atherosclerosis. A growing body of evidence supports the involvement of common proinflammatory cytokines—such as macrophage migration inhibitory factor (MIF), interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF- $\alpha$ )—in the development and progression of both RA and atherosclerosis<sup>(51)</sup>.

## Conclusions

- The prevalence of dyslipidemia among rheumatoid arthritis patients in Sulaimani is high.
- The blood levels of total cholesterol, triglycerides and LDL cholesterols were higher among RA patients.
- HDL cholesterol level was lower among RA patients.
- Dyslipidemia may be a risk factor for rheumatoid arthritis severity and cardiovascular diseases.
- Obesity is a risk factor for rheumatoid arthritis incidence.

## Recommendations

- ❖ Dyslipidemia among RA patients are common and this increase risk of cardiovascular disease and mortality among RA patients, lipid management including greater use of statin therapy may be appropriate to reduce this.
- ❖ Screening programs for RA patients on lipid profile to predict activity and severity of disease, Cardiovascular screening should be recommended every 6 months to once yearly in Sulaimani city.
- ❖ Encouraging the diet restriction programs and physical activities in schools to prevent the obesity.
- ❖ Further national large sized studies on prevalence and effect of hyperlipidemia on RA patients must be supported.
- ❖ Additional prospective, long-term studies are needed to comprehensively determine the role of inflammation and the impact of biologics on lipid levels and cardiovascular outcomes in patients with RA.

## References

1. Gabriel SE, Crowson CS, Maradit Kremers H, Doran MF, Tureson C, O'Fallon WM et al. survival in rheumatoid arthritis : a population based analysis of trends over 40 years .*Arthritis Rheum* 2003;48:54-8.
2. Ward MM. Recent improvement in survival in in patients with rheumatoid arthritis; better outcomes or different study designs ? *Arthritis Rheum* 2001;44:1467-9.
3. Taysi S, Polat F, Gul M, Sari RA, Bakan E. lipid peroxidation, some extracellular antioxidants and antioxidant enzymes in serum of patients with rheumatoid arthritis. *Rheumatol Int* 2002;21:200-4.
4. Heimick, CG; Flson, DT; Lawrence, RC; *et. al*; National Arthritis Data, work group (Jan.2008). "Estimate of the prevalence of arthritis and other rheumatic conditions in the US. part I .*Arthritis and rheumatism* 58(1):15-25.
5. Dorsos A Epidemiology of rheumatoid arthritis ,*Autoimmun REV* 2004; 3(sup11):S20-S22.
6. Majithia V, Geraci SA (2007). "Rheumatoid arthritis: diagnosis and management". *Am.J.Med.* 120(11): 936-936.
7. Ralston S.H., Doherty M. Rheumatoid arthritis ,chapter 25.In: Colledge NR; Walker BR; Ralston S.H.(editors). *Davidson's principles and practice of medicine*, 21th edition. CHURCHILL LIVINGSTONE; 2010,. pp1088-1092.
8. Spellman CW. Strategies for optimizing lipid treatment outcomes. *J Am Osteopath Assoc* 2003; 103:S12-5.
9. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. *Autoimmun Rev* 2006; 5:331-7. Epub 2006 Feb 3.
10. Frostegard J. Atherosclerosis in patients with autoimmune Diseases. *Arterioscler Thromb Vasc Biol* 2005; 25:1776-85. Epub 2005 Jun 23.
11. Toms TE, Panoulas VF, Kitas GD. Dyslipidemia in rheumatological autoimmune diseases. *Open Cardiovasc Med J* 2011; 5:64-75. Epub 2011 Feb 24.
12. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, *et al*. Accelerated atherosclerosis in autoimmune rheumatic diseases. *Circulation* 2005; 112:3337-47.
13. Tureson C, Jacobsson LT, Matteson EL. Cardiovascular comorbidity in rheumatic diseases. *Vasc Health Risk Manag* 2008 4:605-14.
14. Yoo HW. Dyslipoproteinemia in patients with active rheumatoid arthritis: Effects of disease activity, sex, and menopausal status on lipid profiles. *J Rheumatol* 2004; 31: 1746-53.
15. Kelly CA. Extra-articular features of rheumatoid arthritis. *Medicine* 2002; 30: 48-9.
16. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. *J Rheumatol* 2005; 32: 2311-6.
17. Toms TE, Symmons PM, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. *Curr Vasc Pharm* 2010; 8(3): 301-26.
18. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidaemia in inflammatory arthritis. *J Rheumatol* 2002; 29: 462-6.
19. Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. *Ann Rheum Dis* 1994; 53: 551-2.
20. Park YB, Lee SK, Lee WK, *et al*. Lipid profiles in untreated patients with rheumatoid arthritis. *J Rheumatol* 1999; 26: 1701-4.
21. Peters MJ, Vis M, van Halm VP, *et al*. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. *Ann Rheum Dis* 2007; 66: 958-61.
22. Tishler M., Caspi D., Yaron M. – C – Reactive protein level in patients with rheumatoid arthritis, the impact of therapy. *Clinical rheumatology*. 1985;4(3):321-4
23. Avia-Zubieta JA, Choi HK, Sadatsafavi M. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational

- studies. *Arthritis Rheum* 2008; 59:1690–1697
24. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, *et al*: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. *Arth & Rheum* 2005 52(2): 402-411.
25. Lopez-Mejias R, Garca-Bermdez M, Gonzalez-Juanatey C. NFKB1–94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. *Atherosclerosis* 2012; 224:426–429
26. Gonzalez-Gay MA, Gonzalez-Juanatey C, LopezDiaz MJ. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2007; 57:125–132.
27. Alamanos Y, Voulgari PV, and Doros AA: Incidence and prevalence of rheumatoid arthritis based on 1987 American College of Rheumatology criteria: A systematic review. *Semin Arthritis Rheum* 2006; 36(3): 182-88.
28. Abdul-Qahar ZH, Al-Osami MH, Al-Asady: Prevalence of Metabolic Syndrome in Iraqi Patients with Rheumatoid Arthritis. *IOSR Journal of Dental and Medical Science (IOSR-JDMS)*.2013;11(1):69-72.
29. Haye Salinas MJ, Bertoli AM, Lema L, Saucedo C, Rosa J, Quintana R, *et al*. Prevalence of dyslipidemia and elevated cardiovascular risk in patients with rheumatoid arthritis. *Medicina (B Aires)* 2013; 73(1):26-30.
30. Akiyama M, Mawatari T, Nakashima Y, Miyahara H, Yamada H, Okazaki K, *et al*. Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment. *Clin Rheumatol* 2015; 34(11):1867-1875.
31. Scott IC, Ibrahim F, Johnson D, Scott DL, Kingsley GH. Current limitations in the management of cardiovascular risk in rheumatoid arthritis. *Clin Exp Rheumatol* 2012; 30: 228-232.
32. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. *Arthritis Rheum*.2005; 52(2):412–420.
33. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. *Ann Rheum Dis*.2010; 69(1):i61–64.
34. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular comorbidity in rheumatic diseases. *Vasc Health Risk Manag*. 2008; 4(3):605–614.
35. Nisar A, Rasheed U, Aziz W, Farooqi AZ: Prevalence of Dyslipidemia in Autoimmune Rheumatic Diseases. *Journal of the college of Physicians and Surgeons Pakistan* 2012, Vol.22 (4):235-239.
36. Zrour S H, Neffeti F H, Sakly N, *etal* :lipid profile in Tunisian patients with Rheumatoid Arthritis. 2011;Vol 30 (10):pp 1325-1331.
37. Manjunatha Goud BK, Sarsina Devi O, Bhavana N, Devaki RN, Deepa K and Niveditha S. Nutritional Antioxidants and lipid profile in newly diagnosed Rheumatoid arthritis patients. *The International Medical Journal Malasysia IMJM*,2012;Vol 11 (1):5-8.
38. Vinapamula KS, Manohar SM, Bitla AR, Kanduri R, Bhattaram SK and Pemmaraju SR. Evaluation of dyslipidaemia in patients with rheumatoid arthritis in South Indian population. *Indian Journal of Rheumatology*;2013;Vol 8 (4):155-60.
39. Bahlas S and Ahmed MM: Lipid levels and association with disease activity in RA and SLE in Saudi Arabia.2013;Vol 11 (7)1-6
40. Ameer Kh A, Alosami M H, Salih E S: Comparative study of predicting the risk of cardiovascular diseases in active RA Iraqi patients by traditional and non traditional methods; *G.J.B.B*, Vol 2 (4)2013 :522-526.
41. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, *et al*. Atherogenic lipid profile is a feature characteristic of



- patients with early rheumatoid arthritis: effect of early treatment: a prospective, controlled study. *Arthritis Res Ther* 2006; 8:R82.
42. Dursunoglu, D., Evrengul, H., Polat, B., Tanriverdi, H., Cobankara, V., Kaftan, A. & Kilic, M. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. *Rheumatology international*, 2005; 25, 241-5.
43. Attar SM. Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia: Correlation with C-reactive protein levels and disease activity. *Saudi Medical Journal* 2015; 36(6):685-691.
44. Gonzalez-Gay MA, Gonzalez-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. *Ann Rheum Dis* 2014; 73 (7):1281-1283.
45. Dursunoğlu D, Evrengül H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. *Rheumatol Int* 2005; 25: 241-245.
46. Al-kaissi EN, Al-muhtaseb NI, Al-muhtaseb N. The influence of adding antibiotic in treatment of rheumatoid arthritis patients on streptococcus pyogenes carrier rate and on the lipid profile. *International Journal of Pharmacy and Pharmaceutical Sciences* 2015; 7 (2): 245-251.
47. AL-Chetachi MF, Shaher YA. Lipid Status in Rheumatoid Arthritis. 11<sup>th</sup> Scientific Conference of Medical College- Mosul University 2013: 119-124.
48. Mahdi EA, Mohamed LA, Hadi MA. The Relationship between Lipid Profile and Inflammatory Markers in Patients with Early Rheumatoid Arthritis. *Iraqi National Journal of Chemistry* 2012; 47: 391-400.
49. Curtis JR, John A, Baser O. Dyslipidemia and Changes in Lipid Profiles Associated with Rheumatoid Arthritis and Initiation of Anti-TNF Therapy. *Arthritis care & research* 2012; 64(9):1282-1291.
50. Georgiadis AN, Papavasiliou EC, Lourida ES. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study. *Arthritis Research & Therapy* 2006; 8(3):R82.
51. Di Micco P, Ferrazzi P, Libre L, Mendolicchio L, Quaglia I, De Marco M, et al. Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis. *Int J Gen Med.* 2009; 2:141–144.